BOSTON SCIENTIFIC CORP

Boston Scientific Corporation develops, manufactures, and markets medical devices for less-invasive diagnostic and therapeutic procedures across diverse specialties. The company conducts business through two reportable segments: MedSurg and Cardiovascular. Its MedSurg segment supplies minimally invasive equipment for gastrointestinal, urological, and chronic neurological conditions, including single-use scopes, stent systems, laser platforms, and spinal cord stimulators. The Cardiovascular segment provides vascular guidance catheters, drug-eluting therapies, electrophysiology ablation solutions, structural heart closure devices, implantable cardiac rhythm devices, and embolization products. Boston Scientific markets these technologies primarily to hospitals, outpatient clinics, healthcare providers, and group purchasing organizations.

Operating on an international scale, the enterprise distributes devices across 127 countries worldwide via direct sales teams and independent distributor channels. As of year-end 2025, the organization employed approximately 59,000 individuals globally, with about 60 percent located outside the United States. Its global footprint encompasses research facilities, certified production centers, and a government affairs presence in Washington, D.C., though specific corporate headquarters details are not stated in the provided text.

Summary of the business section of Boston Scientific's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had approximately 59,000 employees, of which approximately 60 percent were outside the U.S.”